Publications by authors named "Young Yoon Bang"
Dabigatran acylglucuronide, an active metabolite of dabigatran, exhibits higher plasma concentrations and distinct anticoagulant effects compared to dabigatran, suggesting that it may play a more significant role in overall anticoagulant activity than previously assumed. Idarucizumab, a monoclonal antibody fragment, binds to both free and thrombin-bound dabigatran, neutralizing its anticoagulant effects. However, its efficacy in reversing anticoagulation induced by dabigatran acylglucuronide remains unclear.
View Article and Find Full Text PDFsingle nucleotide polymorphism reduces dabigatran acylglucuronide formation in humans.
Front Pharmacol
January 2025
Background: Dabigatran etexilate (DABE), a prodrug of dabigatran (DAB), is a direct thrombin inhibitor used to prevent ischemic stroke and thromboembolism during atrial fibrillation. The effect of genetic polymorphisms on its metabolism, particularly , has not been extensively explored in humans. This study aimed to investigate the effects of , , and polymorphisms on the pharmacokinetics of DAB and its acylglucuronide metabolites in healthy subjects.
View Article and Find Full Text PDFToxicokinetics of β-Amanitin in Mice and In Vitro Drug-Drug Interaction Potential.
Pharmaceutics
April 2022
Article Synopsis
- A study on β-amanitin, a toxic compound in certain mushrooms, showed that when administered to mice, its plasma concentration increased with higher doses, with a rapid clearance from the system, having a half-life of about 18-34 minutes.
- After intravenous (iv) administration, a significant portion of the compound remained unchanged in the bloodstream, while oral administration resulted in low bioavailability and high fecal recovery.
- The compound primarily concentrated in organs like the intestine, kidneys, and liver, aligning with known effects of amatoxin poisoning, and also showed minimal interaction with major liver enzymes, suggesting it might have limited drug interaction effects.